The FDA has approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. The findings of a recent clinica trial, funded by drugmaker Novo Nordisk, indicate ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

In this trial, which followed more than 3,500 people with type 2 diabetes and chronic kidney disease over an average of 3.4 years, people who took a weekly shot of semaglutide in addition to ...

The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney disease and major cardiac events by 24%, the company said.

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...

Interested in doing the most to protect yourself from stroke or cardiovascular disease? Keep reading to learn more about how ...

Ozempic is now FDA-approved to reduce chronic kidney disease risks in diabetes patients. A Phase 3 trial showed Ozempic reduced kidney disease worsening by 24% and heart-related deaths by 5%.

The FDA has approved Novo Nordisk’s Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks ...

(CNN) — Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated ...